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Key pointsThis prospective, observational study evaluated the effectiveness and clinical feasibility of Biyeom‐go for the treatment of nasal symptoms associated with rhinitis.Biyeom‐go treatment gradually improved total nasal symptom scores and mini‐rhinoconjunctivitis quality of life questionnaire scores in rhinitis patients.IL‐2 levels significantly increased and IL‐8, CCL5, CXCL9, CCL2 and CXCL10 levels were significantly reduced in the nasal lavage fluid after Biyeom‐go treatment.No serious adverse effects or complications were observed.

1. INTRODUCTION {#coa13425-sec-0009}
===============

Rhinitis is a common condition that affects approximately 20%‐25% of the population.[1](#coa13425-bib-0001){ref-type="ref"} Symptoms of rhinitis are often ignored because they are frequently associated with common cold or disappear spontaneously. However, rhinitis can disrupt sleep and has a negative impact on daily function and performance[2](#coa13425-bib-0002){ref-type="ref"}; it can also lead to rhinosinusitis, asthma, otitis media and learning impairment.[3](#coa13425-bib-0003){ref-type="ref"} The economic burden of rhinitis is estimated to be approximately 657 USD per patient each year in the United States,[4](#coa13425-bib-0004){ref-type="ref"} and total healthcare expenditure associated with allergic rhinitis is 272.92 million USD in the Korean population.[5](#coa13425-bib-0005){ref-type="ref"}

Intranasal herbal therapies, including ointments, drops and sprays, are widely used for treating rhinitis in East Asian countries.[6](#coa13425-bib-0006){ref-type="ref"}, [7](#coa13425-bib-0007){ref-type="ref"} Biyeom‐go is an herbal ointment that is clinically used in Korean Medicine to improve nasal symptoms associated with rhinitis. Biyeom‐go is prepared by the addition of Sophorae Radix and Glycyrrhizae Radix et Rhizoma to the Korean Medicine herbal prescription, Hwanglyeonhaedok‐tang (HHT), which consists of Coptidis Rhizoma, Cortex Phellodendri, Scutellariae Radix and Gardeniae Fructus.[8](#coa13425-bib-0008){ref-type="ref"}, [9](#coa13425-bib-0009){ref-type="ref"}

Experimental studies have suggested that HHT has anti‐inflammatory effects by regulating inflammation‐related cytokines, including nitric oxide, prostaglandin E~2~, interleukin (IL)‐6 and tumour necrosis factor (TNF)‐α,[10](#coa13425-bib-0010){ref-type="ref"}, [11](#coa13425-bib-0011){ref-type="ref"}, [12](#coa13425-bib-0012){ref-type="ref"} and anti‐allergic effects by suppressing eosinophil and histamines.[13](#coa13425-bib-0013){ref-type="ref"}, [14](#coa13425-bib-0014){ref-type="ref"} Biyeom‐go, which is derived from HHT, is assumed to reduce various symptoms caused by nasal inflammation, including nasal congestion, rhinorrhea and sneezing, but its safety and effectiveness in humans have not been thoroughly investigated. The aim of the current study was to investigate the safety, effectiveness and clinical feasibility of Biyeom‐go for the treatment of nasal symptoms associated with rhinitis.

2. METHODS {#coa13425-sec-0010}
==========

2.1. Study design and ethical considerations {#coa13425-sec-0011}
--------------------------------------------

This prospective observational clinical study was conducted at the Woosuk Korean Medicine Medical Center in South Korea from November 2016 to March 2017. The protocol was approved by the institutional review board of the Woosuk Korean Medicine Medical Center (identifying code, WSOH IRB 0611‐04) and was registered in the national clinical trial registry, Clinical Research Information Service (registration ID KCT0002197), which is a primary registry of the World Health Organization International Clinical Trials Registry Platform (<http://apps.who.int/trialsearch/Trial2.aspx?TrialID=KCT0002197>). Written informed consent was obtained from all study participants. The study design is summarised in Table [S1](#coa13425-sup-0002){ref-type="supplementary-material"}.

2.2. Participants {#coa13425-sec-0012}
-----------------

Irrespective of rhinitis subtypes, the following criteria were required in order to qualify for inclusion in the study: aged 19‐60 years, continuous nasal symptoms for ≥2 weeks, a total nasal symptom score (TNSS) ≥ 4 and a TNSS congestion score ≥ 2. Patients who were pregnant, currently planning on becoming pregnant or breastfeeding were excluded from the study. After obtaining informed consent, data on demographic characteristics and medical histories were acquired, and a physical examination was conducted to assess eligibility for participation in the study. Patients who were included in the study visited the study site for 4 consecutive weeks (a total of 5 visits).

2.3. Interventions {#coa13425-sec-0013}
------------------

Biyeom‐go, which was manufactured by the Dispensary Pharmacy of Woosuk Korean Medicine Medical Center, consists of 6 medicinal herbs (Coptidis Rhizoma, 170 g; Phellodendri Cortex, 100 g; Scutellariae Radix, 100 g; Gardeniae Fructus, 100 g; Sophorae Radix, 50 g; and Glycyrrhizae Radix et Rhizoma, 50 g) and diluting agents (olive oil, 1 L; yellow wax, 120 g/L; borneol, 20 g; and menthol, 20 g). Quality control data of Biyeom‐go are presented in Figure [S1](#coa13425-sup-0001){ref-type="supplementary-material"}.

Patients were provided with Biyeom‐go and were instructed to use the medicine with a cotton swab \>3 times a day for 4 weeks. Patients used a Biyeom‐go usage diary to record the number of applications, and drug compliance was assessed at every visit based on the diary. During the study period, participants were permitted to take other medications that were not related to rhinitis. If common cold and/or influenza aggravated symptoms, rescue medicine was prescribed. Participants were guided to report all used medications during study periods, and the usage of concomitant treatment was assessed at every visit.

2.4. Outcomes {#coa13425-sec-0014}
-------------

The time‐points at which outcomes were measured are detailed in Table [S1](#coa13425-sup-0002){ref-type="supplementary-material"}. The primary outcome was TNSS. Mini‐rhinoconjunctivitis quality of life questionnaire (RQLQ), nasal endoscopy index, total serum immunoglobulin E (IgE) levels and immunologic factors derived from nasal lavage fluid (NLF) were also examined. TNSS and mini‐RQLQ were assessed at every visit (a total of 5 times). The nasal cavity was assessed using the nasal endoscopy index at every visit.[15](#coa13425-bib-0015){ref-type="ref"} Photographs of the anterior nasal cavity were obtained using a KAU‐3000 HARMONY ENT machine (KASAMA ENT Co., Ltd.). After completion of the study, all photographs were independently scored based on nasal endoscopy index assessment guidelines[15](#coa13425-bib-0015){ref-type="ref"} by two outcome assessors who were not involved in the examinations and were blinded to all patient information. Total serum IgE levels were measured at the first and final visits to identify the rhinitis subtype and any changes in inflammatory/immunologic conditions. NLF was sampled at the first and final visits in accordance with Hentschel\'s method.[16](#coa13425-bib-0016){ref-type="ref"} Immune‐related cytokines, including TNF‐α, interferon (IFN)‐γ, IL‐2, IL‐4, IL‐6, IL‐10, IL‐8 (CXCL8), CCL5 (RANTES), CXCL9 (MIG), CCL2 (MCP‐1) and CXCL10 (IP‐10), were measured in the NLF using commercial Cytometric Bead Array Human Th1/Th2 cytokine and chemokine kits (BD Biosciences) according to the manufacturer\'s protocols.[17](#coa13425-bib-0017){ref-type="ref"}

2.5. Other measures {#coa13425-sec-0015}
-------------------

For the safety of the study, the vital signs of participants were examined at every visit. Information about adverse events (AEs) was provided to all participants. Any AEs potentially related to Biyeom‐go were examined, and any associated measurements and outcomes were assessed.

2.6. Statistical analysis {#coa13425-sec-0016}
-------------------------

Demographic characteristics are expressed as mean ± SD for continuous variables and as frequencies and percentages for categorical variables. Paired two‐sample *t* tests or Wilcoxon\'s signed‐rank tests were used to determine the significance of changes between before and after treatment; these values are represented as the mean difference (MD), 95% confidence interval (CI). Missing values were handled using the last observation carried forward method. The level of significance was set at *P* \< .05 (two‐tailed), and all analyses were performed by an independent statistician using SAS version 9.4 (SAS Institute, Inc).

3. RESULTS {#coa13425-sec-0017}
==========

3.1. Demographic characteristics {#coa13425-sec-0018}
--------------------------------

From December 2016 to March 2017, 60 patients were enrolled in the study. Two subsequently dropped out prior to Biyeom‐go administration, and two dropped out just before the end‐point examination. A total of 56 patients completed the study, and 58 patients were analysed after missing data were imputed for the 2 patients who dropped out just before the end‐point examination.

Patient characteristics are summarised in Table [1](#coa13425-tbl-0001){ref-type="table"}. The final analysis set included 34 men (58.6%) and 24 women (41.4%), with a mean age of 32.5 years. Prior to commencement of the trial, 14 (24.1%) patients had rhinitis for \<5 years, 14 (24.1%) for 6‐10 years, 18 (31.0%) for 11‐20 years, 11 (19.0%) for 21‐30 years and 1 (1.7%) for 31‐40 years. In addition, 7 patients (12.5%) experienced continued rhinitis symptoms for \<30 days, 25 (44.6%) for 31‐90 days, 24 (42.9%) for 91‐180 days and 2 (3.6%) for 181‐365 days. Rhinitis was accompanied by other allergic diseases in 17 patients (29.3%). There were 24 patients with allergic rhinitis, 29 those with vasomotor rhinitis patients and 5 those with non‐allergic rhinitis with eosinophilia syndrome (NARES). No patients had infectious rhinitis.

###### 

Demographic characteristics of the participants

  Classification (N = 58)                            Mean ± standard deviation   
  -------------------------------------------------- --------------------------- ------
  Sex                                                                            
  Male                                               34                          58.6
  Female                                             24                          41.4
  Age (years)                                        32.5 ± 10.9                 
  Under 20                                           2                           3.4
  20‐29                                              28                          48.3
  30‐39                                              9                           15.5
  40‐49                                              15                          25.9
  50‐59                                              4                           6.9
  Height (cm)                                        167.9 ± 7.9                 
  Weight (kg)                                        67.7 ± 13.6                 
  Body mass index (kg/m^2^)                          23.9 ± 3.5                  
  Blood pressure (mm Hg)                                                         
  Systolic                                           119.1 ± 12.2                
  Diastolic                                          78.0 ± 9.9                  
  Heart rate (beats/min)                             81.5 ± 12.8                 
  Body temperature (°C)                              36.7 ± 0.3                  
  Duration of rhinitis (years)                       13.4 ± 8.7                  
  Under 5                                            14                          24.1
  6‐10                                               14                          24.1
  11‐20                                              18                          31.0
  21‐30                                              11                          19.0
  31‐40                                              1                           1.7
  Duration of current rhinitis symptoms (days)       92.6 ± 63.3                 
  Under 30                                           7                           12.5
  31‐90                                              25                          44.6
  91‐180                                             24                          42.9
  181‐365                                            2                           3.6
  Accompanied by other allergic disease                                          
  Yes                                                17                          29.3
  No                                                 41                          70.7
  Rhinitis subtype                                                               
  Allergic rhinitis                                  24                          41.4
  Vasomotor rhinitis                                 29                          50.0
  Non‐allergic rhinitis with eosinophilia syndrome   5                           8.6
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Mean frequency (±SD) of Biyeom‐go application was 3.54 (±0.95) times per day, and the maximum and minimum frequencies of application were 7.54 and 2.37 times per day, respectively.

3.2. Changes in nasal symptom scores {#coa13425-sec-0019}
------------------------------------

As Biyeom‐go treatment progressed, mean TNSSs exhibited significant improvements from baseline (Figure [1](#coa13425-fig-0001){ref-type="fig"}A). At the end of week 1, MD was −1.26, 95% CI \[−1.77 to −0.75\], and the corresponding data at subsequent time‐points were as follows: week 2: −2.07, 95% CI \[−2.63 to −1.51\]; week 3: −2.38, 95% CI \[−2.94 to −1.82\]; and week 4: −2.69, 95% CI \[−3.23 to −2.15\]. Additionally, all nasal symptoms exhibited significant improvements at each visit (Figure [1](#coa13425-fig-0001){ref-type="fig"}B), and significant differences were found between baseline and week 4 in nasal congestion (−0.81, 95% CI \[−0.98 to −0.63\]), rhinorrhea (−0.60, 95% CI \[−0.82 to −0.38\]), itching (−0.57, 95% CI \[−0.78 to −0.36\]) and sneezing (−0.71, 95% CI \[−0.89 to −0.52\]).

![Changes in total nasal symptom score. Results are expressed as mean, 95% confidence interval (error bar). Paired two‐sample *t* tests were used for statistical analysis. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01, ^\*\*\*^ *P* \< .001 and ^\*\*\*\*^ *P* \< .0001 compared with baseline values](COA-44-997-g001){#coa13425-fig-0001}

3.3. Changes in mini‐RQLQ scores {#coa13425-sec-0020}
--------------------------------

As Biyeom‐go treatment progressed, mean mini‐RQLQ scores exhibited significant improvements compared with baseline (Figure [2](#coa13425-fig-0002){ref-type="fig"}A). At the end of week 1, the MD was −11.76, 95% CI \[−14.52 to −8.99\], and the corresponding data at subsequent time‐points were as follows: week 2: −18, 95% CI \[−21.1 to −14.9\]; week 3: −20, 95% CI \[−23.5 to −16.5\]; and week 4: −22.05, 95% CI \[−25.99 to −18.12\]. Subgroup scores were also significantly improved relative to baseline scores (Figure [2](#coa13425-fig-0002){ref-type="fig"}B). Differences were observed between baseline and week 4 in subgroup scores, including those of activities (−3.91, 95% CI \[−4.84 to −2.99\]), practical problems (−3.69, 95% CI \[−4.39 to −2.99\]), nasal symptoms (−5.5, 95% CI \[−6.51 to −4.49\]), eye symptoms (−4.09, 95% CI \[−5.15 to −3.02\]) and 'other symptoms' (−4.86, 95% CI \[−5.78 to −3.94\]).

![Changes in mini‐rhinoconjunctivitis quality of life questionnaire. Results are expressed as mean, 95% confidence interval (error bar). Paired two‐sample *t* tests were used for statistical analysis. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01, ^\*\*\*^ *P* \< .001 and ^\*\*\*\*^ *P* \< .0001 compared with baseline values](COA-44-997-g002){#coa13425-fig-0002}

3.4. Changes in nasal endoscopy index {#coa13425-sec-0021}
-------------------------------------

Nasal endoscopy index was significantly improved at weeks 2, 3 and 4 after Biyeom‐go treatment compared with baseline (Figure [3](#coa13425-fig-0003){ref-type="fig"}A). At the end of week 1, the MD was −0.47, 95% CI \[−1.07 to 0.13\], and the corresponding data at subsequent time‐points were as follows: week 2: −0.90, 95% CI \[−1.51 to −0.28\]; week 3: −1.43, 95% CI \[−2.03 to −0.83\]; and week 4: −1.45, 95% CI \[−2.16 to −0.74\]. More specifically, Biyeom‐go treatment significantly improved nasal mucous membrane colour (−0.38, 95% CI \[−0.72 to −0.04\]), atrophy‐oedema (−0.62, 95% CI \[−0.93 to −0.31\]) and dryness‐dampness (−0.33, 95% CI \[−0.63 to −0.03\]) at week 4 compared with baseline (Figure [3](#coa13425-fig-0003){ref-type="fig"}B).

![Changes in Nasal endoscopy index. Results are expressed as mean, 95% confidence interval (error bar). Paired two‐sample *t* tests were used for statistical analysis. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01, ^\*\*\*^ *P* \< .001 and ^\*\*\*\*^ *P* \< .0001 compared with baseline values](COA-44-997-g003){#coa13425-fig-0003}

3.5. Changes in immune biomarkers {#coa13425-sec-0022}
---------------------------------

Total serum IgE levels at the end‐point examination were decreased from baseline, but the difference was not statistically significant (−13.8, 95% CI \[−31.0 to 3.40\], *P* = .11). IL‐2 levels in the NLF significantly increased at the end‐point examination compared with baseline (1.23, 95% CI \[0.39 to 2.06\], *P* = .005). However, no differences were found in the levels of other immune cytokines. In addition, the NLF levels of chemokines tested---IL‐8, CCL5, CXCL9, CCL2 and CXCL10---were significantly reduced at the end point of the study compared with baseline (Table [2](#coa13425-tbl-0002){ref-type="table"}).

###### 

Changes in immune biomarkers

  Outcome (pg/mL)   Baseline (n = 58)         End point (n = 58)       Mean difference              *P-value* [a](#coa13425-note-0005){ref-type="fn"}
  ----------------- ------------------------- ------------------------ ---------------------------- -------------------------------------------------------
  Total serum IgE   257.1 (136.4 to 377.8)    243.3 (130.1 to 356.5)   −13.8 (−31 to 3.40)          .11
  Cytokines                                                                                         
  IL‐2              0.96 (0.58 to 1.35)       2.19 (1.46 to 2.91)      1.23 (0.39 to 2.06)          .005[\*\*](#coa13425-note-0007){ref-type="fn"}
  IL‐4              0.31 (0.04 to 0.58)       0.87 (0.33 to 1.41)      0.56 (−0.04 to 1.16)         .07
  IL‐6              119.1 (−111.8 to 350.0)   9.0 (2.0 to 16.1)        −110.1 (−335.1 to 114.9)     .33
  IL‐10             0.07 (−0.01 to 0.14)      0.19 (−0.05 to 0.42)     0.12 (−0.12 to 0.37)         .32
  TNF‐α             0.73 (0.19 to 1.28)       1.57 (0.53 to 2.61)      0.83 (−0.14 to 1.81)         .09
  Interferon‐γ      0.12 (−0.04 to 0.27)      0.36 (−0.01 to 0.73)     0.24 (−0.16 to 0.65)         .23
  Chemokines                                                                                        
  IL‐8              820.8 (134.8 to 1506.8)   22.0 (−0.9 to 45.0)      −798.7 (−1486.0 to −111.4)   .02[\*](#coa13425-note-0006){ref-type="fn"}
  CCL5              2.90 (2.13 to 3.68)       0.15 (0 to 0.29)         −2.76 (−3.56 to −1.95)       \<.0001[\*\*\*\*](#coa13425-note-0009){ref-type="fn"}
  CXCL9             496.3 (171.8 to 820.8)    77.2 (−38.2 to 192.6)    −419.1 (−765.7 to −72.43)    .02[\*](#coa13425-note-0006){ref-type="fn"}
  CCL2              35.1 (22.7 to 47.5)       2.9 (−0.3 to 6.1)        −32.2 (−44.7 to −19.7)       \<.0001[\*\*\*\*](#coa13425-note-0009){ref-type="fn"}
  CXCL10            579.8 (327.8 to 831.8)    156.4 (−73.9 to 386.7)   −423.4 (−763.9 to −82.8)     .02[\*](#coa13425-note-0006){ref-type="fn"}

Results are presented as mean (95% CI).

Abbreviations: IgE, Immunoglobulin E; IL, interleukin; TNF, tumour necrosis factor.

paired *t* test.

*P* \< .05,

*P* \< .01,

*P* \< .001 and

*P* \< .0001
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3.6. Adverse events and concomitant medications {#coa13425-sec-0023}
-----------------------------------------------

Of the 58 patients, 14 reported the following AEs: common cold (6), influenza (2), headache (2), gastritis (1), enteritis (1), throat discomfort (1) and cold and gastric cramps (1). No serious adverse events were reported.

During the study period, 2 patients were taking anti‐hypertensive medication, 1 patient was taking anti‐diabetes medication, 1 patient was taking aspirin for preventing cardiovascular disease, 1 patient was taking anti‐depressive medication and 1 patient was taking Finasteride for alopecia. In addition, 1 patient took herbal medicine for 2 days because of gastric discomfort, and 1 patient took paracetamol (1 tablet) because of headache. Among 58 participants, 7 had taken common cold or influenza‐related drugs. Among the 7 patients, 4 had taken herbal medicine for 2 days because of common colds; 1 patient had taken oseltamivir (Tamiflu) for 3 days because of type A influenza; 1 patient had taken oseltamivir (Tamiflu), pseudoephedrine hydrochloride, levodropropizine and bepotastine salicylate at the last visit because of Type A influenza; and another patient had taken pseudoephedrine hydrochloride, prednisolone, bepotastine salicylate and paracetamol for 6 days because of common cold. Excluding the 7 participants who had taken common cold or influenza‐related medications, data collected from the remaining 51 participants are presented in Table [S2](#coa13425-sup-0003){ref-type="supplementary-material"}.

4. DISCUSSION {#coa13425-sec-0024}
=============

4.1. Synopsis of key findings {#coa13425-sec-0025}
-----------------------------

In the present study, Biyeom‐go treatment gradually reduced TNSSs, nasal congestion, rhinorrhea, itching and sneezing and improved mini‐RQLQ scores and subgroup scores, including those of activities, practical problems, nasal symptoms, eye symptoms and 'other symptoms'. Moreover, Biyeom‐go treatment improved inferior nasal concha oedema‐atrophy, nasal mucous membrane dryness‐dampness and intranasal surface colour. Collectively, these findings suggest that Biyeom‐go improves the nasal symptoms and quality of life and alleviates intranasal mucosal conditions.

Biyeom‐go treatment tended to reduce total serum IgE, but this reduction was not statistically significant. The current study included rhinitis patients irrespective of the presence or absence of allergic rhinitis, and 28 included participants had normal serum IgE levels prior to Biyeom‐go treatment. Further studies are needed to evaluate the effects of Biyeom‐go in allergic rhinitis patients with elevated serum IgE levels.

IL‐2 has an immunomodulatory effect and plays an important role in the pathogenesis of allergic rhinitis via regulatory T‐cell activation.[18](#coa13425-bib-0018){ref-type="ref"} In the present study, IL‐2 levels were significantly higher after than before treatment. It is assumed that Biyeom‐go can regulate IL‐2 expression, resulting in the activation of regulatory T cells that suppress immune responses associated with rhinitis.

In the current study, all chemokines investigated, including IL‐8, CCL5, CXCL9, CCL2 and CXCL10, which are members of the family of pro‐inflammatory basic chemoattractant polypeptides, were significantly reduced in NLF after Biyeom‐go treatment. Previous studies have suggested that IL‐8 in the NLF recruits and activates neutrophils, contributing to the inflammation that coincides with nasal symptoms observed in rhinitis patients.[19](#coa13425-bib-0019){ref-type="ref"} CXCL10 and CXCL9 may play roles in the development of nasal allergic inflammation and are elevated in NLF in allergic rhinitis patients.[20](#coa13425-bib-0020){ref-type="ref"} Additionally, the level of CCL5, which is involved in leucocyte recruitment in the allergic nasal mucosa, is also elevated in allergic rhinitis patients.[21](#coa13425-bib-0021){ref-type="ref"} These observations suggest that Biyeom‐go regulates intranasal inflammatory and allergic reactions and reduces chemokine levels. In summary, Biyeom‐go might improve nasal symptoms by suppressing leucocytes of the nasal mucosa that are involved in rhinitis‐associated inflammatory and allergic reactions, resulting in improvements in the intranasal condition.

4.2. Strengths and limitations of the study {#coa13425-sec-0026}
-------------------------------------------

This study is the first clinical trial evaluating the effects of the topical herbal ointment, Biyeom‐go, in rhinitis patients. Effectiveness was assessed via patient‐reported subjective questionnaires, objective nasal endoscopy index and immune biomarker levels in NLF, which can reflect the characteristics of nasal cavity reactions to the topical administration of potential therapeutic agents.

No serious AEs occurred during the current study, suggesting that Biyeom‐go is safe for a treatment period of 4 weeks. Interestingly, common cold was the most frequently observed AE during the study. Notably, this study was conducted in the winter season, during which there is typically a higher prevalence of different viral infections, including respiratory syncytial virus, influenza virus and coronavirus infections, throughout the community.[22](#coa13425-bib-0022){ref-type="ref"} In the present study, improvements in rhinitis were observed after Biyeom‐go treatment, although common cold and influenza might aggravate rhinitis symptoms.

The current study has several limitations. We hypothesised that Biyeom‐go may alleviate nasal symptoms associated with rhinitis based on our prior experiences; therefore, this study included all rhinitis patients regardless of rhinitis phenotypes and endotypes. Rhinitis phenotypes and endotypes are numerous and diverse and encompass many different pathologic and treatment mechanisms[23](#coa13425-bib-0023){ref-type="ref"}; thus, treatment effects may differ in patients with different rhinitis phenotypes. Therefore, future studies and clinical trials will need to incorporate differentiation between rhinitis phenotypes and endotypes into their designs.

In addition, the duration of action of a highly molecularly standardised and characterised drug can often be reliably estimated based on its pharmacokinetics, and optimal dosage regimens can be determined based on human pharmacological studies.[24](#coa13425-bib-0024){ref-type="ref"} However, the duration of action of herbal preparations, such as the ointment used in the present study, is not easily assessed due to the presence of multiple bioactive compounds. Patients in the present study were instructed to apply the Biyeom‐go ointment \>3 times per day based on our prior experiences. Thus, further pharmacokinetic studies are needed to determine an appropriate dosage regimen.

A third limitation of the present study is that there was no comparison between the Biyeom‐go treatment group and a placebo group. The aim of this study was to explore the feasibility of Biyeom‐go in clinics before conducting a randomised controlled trial, and we thus investigated the safety and effectiveness of Biyeom‐go without controls. Because of selection and information bias, the uncontrolled study might have overestimated the effects of the tested intervention. Moreover, the symptoms of seasonal AR and perennial rhinitis, including vasomotor rhinitis and NARES, can fluctuate; therefore, an appropriate control group is essential to assess the effects. Therefore, future randomised controlled trials are needed to confirm the effects of Biyeom‐go.

4.3. Clinical applicability of the study {#coa13425-sec-0027}
----------------------------------------

The participants included in the present study were treated with Biyeom‐go alone to evaluate its clinical effects in rhinitis patients. Considering its efficacy in terms of improvements in TNSSs, mini‐RQLQ scores, nasal endoscopy index and immune biomarker levels, as well as a complete absence of serious AEs, in patients with rhinitis; Biyeom‐go treatment is feasible for clinical practice and is a safe option for the treatment of rhinitis. This study is the first to examine the clinical effectiveness of Biyeom‐go. Our findings suggest that intranasal Biyeom‐go administration is safe, and a large‐scale controlled clinical trial is warranted to determine the efficacy of Biyeom‐go for the management of rhinitis symptoms.
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